Analysts forecast that Johnson & Johnson (NYSE:JNJ) will announce earnings per share of $2.00 for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Johnson & Johnson’s earnings, with the lowest EPS estimate coming in at $1.99 and the highest estimate coming in at $2.02. Johnson & Johnson posted earnings per share of $2.05 in the same quarter last year, which would indicate a negative year over year growth rate of 2.4%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, October 15th.
According to Zacks, analysts expect that Johnson & Johnson will report full-year earnings of $8.60 per share for the current financial year, with EPS estimates ranging from $8.57 to $8.62. For the next financial year, analysts expect that the company will report earnings of $9.09 per share, with EPS estimates ranging from $8.81 to $9.22. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. The business had revenue of $20.56 billion for the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The company’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period last year, the company earned $2.10 earnings per share.
Several analysts have recently weighed in on JNJ shares. Barclays started coverage on Johnson & Johnson in a research note on Friday, June 21st. They set a “hold” rating and a $140.00 target price for the company. Raymond James cut their price target on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 17th. Bank of America reissued a “hold” rating and issued a $150.00 price target on shares of Johnson & Johnson in a report on Tuesday, July 16th. Goldman Sachs Group set a $169.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, August 27th. Finally, Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $150.60.
NYSE:JNJ traded up $1.62 during mid-day trading on Friday, hitting $131.17. The company had a trading volume of 5,885,667 shares, compared to its average volume of 7,115,274. The business has a fifty day simple moving average of $130.11 and a 200-day simple moving average of $135.97. The firm has a market capitalization of $335.04 billion, a price-to-earnings ratio of 16.04, a PEG ratio of 2.15 and a beta of 0.68. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99.
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were given a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.90%. The ex-dividend date of this dividend was Monday, August 26th. Johnson & Johnson’s payout ratio is currently 46.45%.
Institutional investors have recently modified their holdings of the company. Virtus ETF Advisers LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at $25,000. Krane Funds Advisors LLC acquired a new position in Johnson & Johnson during the 2nd quarter worth $26,000. Crewe Advisors LLC boosted its position in Johnson & Johnson by 725.9% during the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after acquiring an additional 196 shares during the period. Permanens Capital L.P. grew its stake in shares of Johnson & Johnson by 50.0% in the second quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after purchasing an additional 100 shares in the last quarter. Finally, Evolution Wealth Advisors LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth $40,000. Institutional investors and hedge funds own 72.12% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: What is the significance of a dead cat bounce?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.